Pneumonia research to reduce childhood mortality in the developing world

J. Anthony G. Scott,1,2 W. Abdullah Brooks,3 J.S. Malik Peiris,4 Douglas Holtzman,5 and E. Kim Mulholland6

1Wellcome Trust/KEMRI Research Programme, Kilifi, Kenya. 2Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom. 3Centre for Health and Population Research, International Centre for Diarrhoea Disease Research, Dhaka, Bangladesh. 4Department of Microbiology, University Pathology Building, Queen Mary Hospital, University of Hong Kong, Hong Kong Special Administrative Region, People’s Republic of China. 5Infectious Diseases Development, Global Health Program, Bill and Melinda Gates Foundation, Seattle, Washington, USA. 6Infectious Disease Epidemiology Unit, London School of Hygiene and Tropical Medicine, London, United Kingdom.

Pneumonia is an illness, usually caused by infection, in which the lungs become inflamed and congested, reducing oxygen exchange and leading to cough and breathlessness. It affects individuals of all ages but occurs most frequently in children and the elderly. Among children, pneumonia is the most common cause of death worldwide. Historically, in developed countries, deaths from pneumonia have been reduced by improvements in living conditions, air quality, and nutrition. In the developing world today, many deaths from pneumonia are also preventable by immunization or access to simple, effective treatments. However, as we highlight here, there are critical gaps in our understanding of the epidemiology, etiology, and pathophysiology of pneumonia that, if filled, could accelerate the control of pneumonia and reduce early childhood mortality.

Introduction

Every year 1.9 million children under 5 years of age die from pneumonia (1). Indeed, it is the leading cause of child death in the world. Pneumonia is an acute illness in which the alveolar air spaces of the lung become inflamed and filled with fluid and white blood cells, giving rise to the appearance of consolidation on the chest radiograph. It can be caused by bacterial, viral, or parasitic infection as well as by noninfectious agents. Most severe cases of pneumonia are caused by bacteria, of which the most important are Streptococcus pneumoniae (pneumococcus) and Haemophilus influenzae. In developing countries, where patients are often treated without seeing a doctor, the WHO defines clinical pneumonia simply as an acute episode of cough or difficulty breathing associated with an increased respiratory rate (2).

Pneumonia is a disease of all ages, and in adult medical wards across the developing world it is one of the most common admission diagnoses. In contrast to the industrialized world, pneumonia is found characteristically in younger adults, who have a substantial inpatient mortality of 5%–23% (3). The pathogens causing pneumonia in children and adults are similar, and most respiratory pathogens are transmitted effectively between generations within households. In the United States, preventing pneumonia in children by vaccinating against pneumococcal disease has resulted in less pneumonia in adults (4). However, little is known about adult pneumonia in developing countries, and research is rare outside the context of emerging infections (3). There are thus considerable opportunities for pneumonia research on adults. However, in this Review, we concentrate on childhood pneumonia and specifically on research to reduce the unacceptable magnitude of child deaths from this disease.

Historically, pneumonia was the main cause of child death in developed countries, and in the United States in 1900, it is estimated that pneumonia killed 47 of every 1,000 children before the age of 5 years (5). Improvements in nutrition and living standards in the United States in the first 40 years of the 20th century led to a substantial reduction in pneumonia mortality well before antibiotics became available as an effective treatment (Figure 1 and refs. 6–8). However, in the low-income countries of Asia and Africa, pneumonia is still the main cause of child death. In developing countries, over one-quarter of children die from an episode of clinical pneumonia each year throughout the first 5 years of their lives (9). On average, 2%–3% of children each year have pneumonia severe enough to require hospitalization, and many of these disease episodes are potentially fatal (9). Thus, for every 1,000 children born, about 100–150 episodes of severe pneumonia arise during the first 5 years of life, most during the first 2 years. Approximately 21% of child deaths are due to pneumonia (1), and many developing countries have mortality rates of 60–100 per 1,000 children under 5 years of age (10); this suggests that of every 1,000 children born alive, 12–20 die from pneumonia before their fifth birthdays.

Although we know the number of children who die of pneumonia in developing countries, few of the causal factors leading to death have been elucidated. Mortality is associated with poverty and with malnutrition; critically, we do not yet know the extent to which it is caused by lack of access to health care. If access to care is inversely related to mortality, the impact of new diagnostics, medical treatments, and vaccines will be substantially constrained. Therefore, the first priority for pneumonia research is a better understanding of the epidemiology of fatal pneumonia. Increased understanding of this, as well as more detailed information about the etiology and pathophysiology of the disease, should guide new approaches to tackle the immense global problem of child deaths from pneumonia.
recently, the WHO has also pioneered the standardized interpretation and with improved housing and reduced indoor air pollution.

Empiric treatment guidelines. The primary rationale for etiological research in developing countries is to determine empiric treatment guidelines. Laboratories cannot determine etiology in sufficient time to influence management effectively, and in any case, few hospitals have the resources to investigate patients on an individual basis. Here, there are three challenges. First, it is difficult to obtain appropriate specimens from the lower respiratory tract. Children cannot normally produce sputum, and so the most useful etiologic data have been obtained in lung aspirate studies that provide microbiological evidence with the strongest claim on pneumonia causality (13). However, because lung aspirates are invasive, they are only conducted at a small number of research centers in developing countries (14, 15). Second, many pathogens that cause pneumonia are fastidious and require sophisticated laboratory culture systems for growth or replication. Third, existing tests for most pathogens that cause pneumonia are imperfect, and there is therefore no gold standard against which to test new diagnostics.

Isolation of bacteria from the blood of patients with clinical signs of lung infection is highly specific for bacterial pneumonia, but it has a sensitivity of less than 15% (12). Conventional diagnosis of viral pneumonia through cell culture or immunofluorescence techniques also has poor sensitivity (16). PCR can increase the sensitivity of pathogen detection (17–21), and multiplex PCR formats can improve throughput (16, 22). For example, the Respiratory MultiCode–PLx Assay (RMA; EraGen Biosciences) integrates multiplex PCR with microsphere flow cytometry to allow simultaneous identification of eight groups of respiratory virus (respiratory syncytial virus [RSV]; paramyxovirus; influenza A and influenza B; human rhinovirus; enteroviruses; metapneumovirus; adenovirus B, adenovirus C, and adenovirus E; and coronaviruses). Compared with conventional diagnostic methods, this technique increases the number of pathogen-positive samples roughly 3-fold (16).

Similarly, the mass tag technique links multiplex PCR for both bacterial and viral pathogens to the detection of stable organic molecules with unique molecular weights, known as mass tags (23). These molecules are coupled to the oligonucleotides used in PCR through UV-cleavable linkers and are detected with mass spectrometry following purification of amplification products. Because each oligonucleotide has a unique mass tag, and a positive signal is defined as the presence of paired mass tags, this gives increased confidence that the signal is the result of a specific amplification reaction. New microarray and mass spectrometry methods permit an even broader survey of potential pathogens (24–27). The challenge these technologies present to epidemiological research is to determine the causal attribution of organisms identified in blood or nasal secretions in the etiology of pneumonia.

Diagnostic tests to guide individual case management. For a new diagnostic test to be effective in the developing world it must be rapid, simple to execute, and inexpensive. For example, in adults, simple immunochromatographic strip tests can detect bacterial polysaccharides in urine and facilitate rapid diagnosis (28, 29). Unfortunately, this approach lacks specificity in children because, unlike adults, they often carry respiratory pathogens in their nasopharynx and therefore frequently excrete bacterial polysaccharides (30). For example, 60%–90% of children in developing countries are carriers of S. pneumoniae (31).

Numerous attempts have been made to identify biomarkers that can rapidly differentiate bacterial from viral pneumonia and thus focus antibiotic therapy on those most likely to respond. Serum levels of the acute phase proteins procalcitonin and C-reactive protein (CRP) are elevated in pneumonia, but their specificity, sensitivity, and predictive values vary widely in validation studies (32–34). Nonetheless, a CRP level of 40 mg/dl or greater, combined with a clinical diagnosis of pneumonia, identifies a greater proportion of pneumococcal pneumonias (defined as preventable by pneumococcal vaccination) than does clinical diagnosis alone (35). A number of cytokines and chemokines, including IL-1 receptor antagonist, IL-1β, IL-6, IL-8, G-CSF, TNF-α, and soluble triggering receptor expressed on myeloid cells (sTREM) have also shown diagnostic potential in severe bacterial infections, although none of these has yet been validated in the developing world for diagnosis of pneumonia (36–41).

Respiratory viruses and pneumonia with multiple etiologies. In industrialized countries, influenza strains other than H3N1 cause pneumonia.
Etiology of severe pneumonia in children in developing countries.

Qualitative representation of the combined results of vaccine probe analyses (12, 113), studies of blood and lung aspirate cultures (14, 111, 153–155), and virus studies (128, 156) in predominantly HIV-uninfected children. Note that children might be infected by two or more lung pathogens simultaneously. Single-etiology studies and studies of children in the developed world suggest the undiagnosed portion might be attributable, at least in part, to respiratory viruses (adenoviruses, influenza viruses, parainfluenza virus, human metapneumovirus, cytomegalovirus, rhinovirus, enteroviruses, and coronaviruses), *Pneumocystis jirovecii*, *Mycoplasma pneumoniae*, *Chlamydia trachomatis*, and *Chlamydia pneumoniae*. Etiology differs substantially in young infants (112), HIV-infected children (157), and malnourished children (15) as well as by region; for example, *S. aureus* accounted for one-quarter of the cases of pneumonia in a large study in Chile (158).

and lower respiratory disease in children, often leading to hospitalization (42, 43). However, their role in mortality and morbidity in developing countries is poorly defined. In a study in rural Thailand, influenza virus was detected in approximately 10% of all patients hospitalized with pneumonia, with infants and those aged 75 years or older being at greatest risk (44). An underlying respiratory disease was found in 26% of older patients admitted with pneumonia caused by infection with the influenza virus, but underlying disease was uncommon in children under 5 years of age (44). Although bacteria and viruses can cause pneumonia independently, influenza and *S. pneumoniae* can interact to exacerbate severe pneumonia (45, 46), and at least one animal model provides evidence of lethal synergism (47). Specifically, the influenza neuraminidase protein facilitates pneumococcal invasiveness by stripping sialic acid from receptors on epithelial cells lining the respiratory tract. Pneumococci can attach to these receptors, enhancing their invasiveness. This viral contribution to the initiation of pathology often goes unrecognized. Conversely, preventing the pneumococcal complications of viral infections by pneumococcal vaccination can reduce the morbidity associated with pneumonia caused by infection with respiratory viruses (48).

The increased application of molecular methods of diagnosis has revealed that patients with acute respiratory infections (ARIs), including pneumonia, often have multiple viruses detected in the respiratory tract (49). The relative contributions of these pathogens to the genesis of respiratory pathology and their interactions with bacterial pathogens are clear opportunities for future research.

**Pneumonia of unknown etiology and emerging lung infections.** Studies of children in developing countries suggest that about half of all pneumonias are caused by either *H. influenzae* or *S. pneumoniae* (Figure 2). However, it is not always possible to define the causative pathogen, and even with sophisticated laboratory techniques 25%–33% of cases of pneumonia worldwide are not attributed to any pathogen (16, 50). An unresolved question in the field of pneumonia research is the extent to which cases without a definable cause either reflect the poor sensitivity of current diagnostic tools for known pathogens or point to novel uncharacterized pneumonia pathogens. Indeed, the recent association of novel coronaviruses and rhinoviruses with respiratory disease in humans (51–53) highlights the need for an adaptable approach to the etiological investigation of pneumonia. It is likely that new pathogens will continue to emerge and that the etiological profile of pneumonia will alter considerably when the currently dominant pathogens, *H. influenzae* and *S. pneumoniae*, decline following vaccination.

The pathogens that best illustrate the challenge posed by newly emerging lung infections are the SARS coronavirus (SARS-CoV) and avian influenza H5N1. Both viruses cause pneumonia in children as well as adults. H5N1 influenza causes severe pneumonia in children, whereas the SARS-CoV causes milder disease in children, for reasons that remain obscure (54–56). The SARS epidemic illustrated the importance of surveillance for early recognition and rapid response to emerging pathogens. Indeed, the control of SARS was a triumph for global public health, and it was achieved by simple public health measures prior to the availability of vaccines and drugs. However, this success was possible only because the SARS-CoV is poorly transmissible in the first few days of the illness (57). Such favorable characteristics are unlikely to be replicated in a full-blown influenza pandemic.

In developed countries, vaccine control is likely to prove pivotal in defense against emerging pathogens that cause pneumonia (58). Indeed, intense effort is being directed to the development of vaccines against the animal coronaviruses that could be the precursors of a future SARS-like disease and also existing strains of avian influenza H5N1, such that in the event of human epidemic a vaccine might be more easily and more rapidly produced. However, selection of the antigens to which the vaccines should be targeted is proving difficult given the broad antigenic diversity of the animal coronaviruses (59) and the existing strains of avian influenza H5N1.

In developing countries, the inaccessibility of vaccines and antiviral drugs suggests that the only means of controlling outbreaks of emerging respiratory infections or an influenza pandemic will be simple public health measures such as social distancing, masks, and hand hygiene. Surprisingly, there are few studies on the efficacy of such interventions on the transmission of influenza or other respiratory viruses (60). Mathematical models are useful to predict the effectiveness of interventions at the population level, but these models are dependent on the accuracy of their transmission and intervention parameters. Such data can only come from well-designed, community-based epidemiological studies. With the tools of modern diagnostics, genomics, and immunology, it is now timely to revisit the classical Virus Watch studies of respiratory infections in families in the 1960s (61). Models and epidemiological studies should also consider heterogeneity in individual infectiousness, which has been observed in SARS, measles, and smallpox. Paradoxically, mathematical models predict that epidemics that arise out of human interactions of extraordinary infectiousness, i.e., superspreading events, might be especially susceptible to extinction and easier to curtail through individual control measures (62).

Both SARS and avian influenza H5N1 are zoonotic in origin, and this emphasizes the need for better understanding of the microbial ecology of domestic and wild animals and for closer collaboration.
among scientists in human, agricultural, and wildlife research. The elucidation of viral, genetic, and environmental determinants that permit or restrict the interspecies transmission of these pathogens is a major research challenge.

Pathophysiology of and immunity to pneumonia

The pathophysiology of pneumonia and immune regulation of the inflammatory response to lung infection are poorly understood, and few of the factors causing severe disease or death have been identified. Correction of hypoxia and zinc supplementation are two interventions that have proven efficacious, but research into the control of inflammation also offers considerable potential to improve outcomes.

Hypoxia. Severe childhood pneumonia is characterized by respiratory distress, which includes lower chest wall indrawing and frequently hypoxia. In young children, lower chest wall indrawing occurs because they have a soft sternum, horizontal ribs, and poor intercostal muscle development; when they try to generate greater negative pressure to inflate the lungs because of the presence of consolidation and lower airway obstruction, their lower chest wall collapses. Because airflow resistance increases inversely to the fourth power of the radius, small changes in airway diameter as a result of inflammation substantially reduce airflow. Hypoxia is thought to result primarily from ventilation/perfusion mismatch, although children with pneumonia in developing countries do respond to treatment with small amounts of oxygen (63). Without correction, hypoxia and acidosis set the stage for respiratory failure and death.

Estimates of the prevalence of hypoxia among children with pneumonia vary with hospital admission policies and with the effects of altitude. Up to 59% of admitted children are found to have a saturation of peripheral oxygen (SPO₂) lower than 90% (moderate hypoxia) and up to 29% have SPO₂ lower than 70% (severe hypoxia) (64–66). Among Kenyan children hospitalized with pneumonia, those with hypoxia were four times more likely to die than those without hypoxia (64). The clinical signs of pneumonia identify hypoxia poorly in children (64, 65), and in Papua New Guinea, using pulse oximetry to guide oxygen therapy rather than using clinical signs alone reduced mortality by 35% (66). The WHO recommends providing oxygen, via either nasal prongs or catheter, to all children exhibiting any of the following signs: moderate hypoxia, cyanosis, inability to feed, or a respiratory rate greater than 60 breaths per minute (67). However, adoption of this approach in developing countries has been slow. There are several reasons for this, including insufficient oxygen supply, misunderstanding of the specifications of pulse oximeters appropriate for developing countries, lack of cost-effectiveness data, and ignorance of the prevalence and distribution of hypoxemia (67, 68). Furthermore, most hospitals in developing countries purchase oxygen in cylinders, which is expensive, rather than investing in more economical oxygen concentrators (67, 69). The potential impact of this effective, low-cost intervention on child mortality deserves urgent investigation.

Vitamin A and zinc supplementation. Observational studies report that children with vitamin A deficiency have a 2-fold or higher risk of respiratory tract infection and death from pneumonia (70, 71). Although vitamin A supplementation reduces mortality among children under 2 years of age following infection with the measles virus (72), it has no apparent benefit in the treatment (73) or prevention (74, 75) of pneumonia. The observed association between pneumonia and vitamin A deficiency might therefore be attributable to other confounding risk factors, such as zinc deficiency, which occurs in the same populations and is also associated with increased risk of acquiring respiratory infections (76). Indeed, zinc supplementation reduces the incidence of pneumonia by up to 40% and reduces the duration of hospitalization by 25% (77, 78). Moreover, it can substantially reduce mortality in children under 2 years of age, primarily as a result of its effects on severe pneumonia (79); this reduction is sustained for children up to 5 years of age (80).

How zinc supplementation reduces the incidence and severity of pneumonia is not known, but there is evidence to suggest that it acts through the acute phase of the immune response to infection (81). The acute phase of an immune response to lung infection involves macrophages, lymphocytes, NK cells, and antibody-dependent cytotoxicity (82). Zinc decreases infection-related lung inflammation directly, and zinc deficiency enhances airway inflammation and cellular damage (83). In animal models, bacterial growth inhibition and host cell regeneration are both increased in the presence of zinc (84). Because these effects are pathogen independent, zinc supplementation offers substantial promise as a way to decrease child mortality due to pneumonia in developing countries, where limited resources constrain the determination of etiology.

A substantial constraint on the utility of zinc supplementation in preventing pneumonia is the relative paucity of data from Africa, where both malaria and HIV might modify its protective effect. A single study from Lesotho reported that zinc supplementation resulted in a modest reduction in pneumonia morbidity, but it was confined to children with severe protein-energy malnutrition (85). Elsewhere, a study from Zanzibar, which is holoendemic for malaria, reported a statistically nonsignificant 12% reduction in pneumonia-related mortality among children receiving zinc supplements (86), and a zinc supplementation trial in South Africa among children 6–60 months of age infected with HIV-1 reported no increase in HIV-1 viral load and a statistically significant 14% reduction in the incidence of diarrhea (87). Neither study, however, reported effects on pneumonia incidence.

The role of zinc in pneumonia treatment is also unclear, because results from hospital-based studies using different methodologies are inconsistent (78, 88–91). Furthermore, the use of zinc supplementation in outpatient settings, where most children with pneumonia are treated, has not been explored at all. In summary, zinc supplementation reduces pneumonia incidence prophylactically and reduces the risk of pneumonia-related mortality. More evidence is required to determine its acute effects as a treatment for pneumonia.

Innate immunity. In pneumonia research, acquired immunity has received considerable attention but the role of innate immunity, particularly relating to severe childhood pneumonia, has not. Animal models show that TLRs are essential for innate immunity to bacteria (92, 93) and viruses (94, 95), promoting cytokine-mediated inflammation. Cytokines and chemokines, including TNF-α, IL-6, IFN-γ, IL-1β, IL-4, IL-8, macrophage inflammatory protein–1α, and eotaxin, promote inflammation and pathogen clearance (96). Antiinflammatory cytokines such as IL-10 then reduce inflammation (Figure 3 and ref. 96). When inflammation is not balanced by antiinflammation, it causes lower airway obstruction and cellular damage (96, 97) and can even facilitate bacterial growth (98). The severity of lung damage and high mortality caused by infection with H5N1 influenza and the 1918 pandemic strain of influenza might be explained by unbalanced inflammatory responses that can be induced by these viruses in vitro and in macaques (99, 100).
RNA virus: Viral envelope fusion protein (RSV) or double-stranded RNA

**Figure 3**

TLRs and the cytokine response to bacterial and viral pathogens. Gram-negative bacteria (e.g., *E. coli*), Gram-positive bacteria (e.g., *S. pneumoniae*), and RNA viruses attach to different receptors on the respiratory epithelium, triggering a proinflammatory cascade that results in activation of macrophages and polymorphonucleocytes. The latter, in turn, trigger antiinflammatory negative feedback to shut down inflammation. MIP-1α, macrophage inflammatory protein–1α.

Similar to zinc, TLRs and cytokines both modulate lung inflammation (83, 92, 96). An understanding of the balance of their actions would help explain the mechanism of action of zinc and might lead to new interventions that could control inflammation, reduce severity, and prevent death.

**Preventing pneumonia through vaccination**

Immunization has enormous potential to reduce the burden of childhood deaths from pneumonia in developing countries. Vaccines are in development against several pathogens that cause pneumonia, including parainfluenza virus, *Staphylococcus aureus*, and *Mycobacterium tuberculosis* (101–103). Here we limit our discussion to vaccines against the most common pneumonia-causing pathogens: *H. influenzae* type b (Hib), pneumococcus, and RSV.

*Conjugate vaccines against Hib and pneumococcus.* Polysaccharide-protein conjugates illustrate how simple laboratory insights can be translated into substantial public health gain. The polysaccharides in the capsules of Hib and pneumococcus are the targets of mature humoral immunity and elicit T cell–independent responses (104). Children can respond optimally to these antigens only after the first year of life, when their immune systems have matured (105, 106). However, in order to circumvent the limitations of the infant immune system, developers of polysaccharide-protein conjugates have used the 1929 observation of Avery and Goebel that conjugation of serum proteins to synthetic nonantigenic carbohydrates produced an antigenic compound that induced an immune response directed toward the carbohydrate component (107). The protein moiety stimulates T cell–dependent humoral immunity, which develops early in infancy, but the specificity of the response is focused on the polysaccharide moiety.

Polysaccharide-protein conjugate vaccines to prevent diseases caused by Hib or seven serotypes of pneumococcus were licensed in industrialized countries in 1990 and 2000, respectively, and have virtually eliminated disease caused by the targeted serotypes among immunized populations (108, 109). Early experience with the Hib vaccine in developing countries has confirmed its effectiveness (110). The use of these conjugate vaccines has also provided substantial insights into the epidemiology of pneumonia. For example, in The Gambia, results of early studies of blood and lung aspirate cultures suggested that Hib was the cause of approximately 7% of cases of pneumonia (111, 112). Later, in a randomized controlled trial, the observed efficacy of the Hib conjugate vaccine against radiologically confirmed pneumonia was 21%, indicating that at least this fraction of pneumonia was caused by Hib (113). A subsequent trial in The Gambia of a 9-valent pneumococcal conjugate vaccine (PCV), so called because it contains capsular antigens of nine serotypes of pneumococcus, quantified the proportion of radiologically confirmed pneumonia caused by these pneumococcal serotypes at 37% (12); in The Gambia, Hib and nine serotypes of pneumococcus were the cause of over 50% of cases of radiologically confirmed pneumonia.

PCVs protect vaccinated children by inducing neutralizing IgG in serum (114). They also reduce the prevalence of nasopharyngeal carriage of the pneumococcal serotypes included in the vaccine (vaccine-type pneumococci; ref. 115), possibly because serum IgG seeps across the mucosal surface (116). The nasopharynx of young children is the principal natural reservoir of pneumococcus, and reduced carriage leads to decreased transmission and a decline in pneumococcal disease in unvaccinated individuals — herd protection. In America, two cases of vaccine-type pneumococcal disease have been prevented among nonvaccinated individuals for every one prevented directly by immunization (109).

The overall prevalence of nasopharyngeal carriage of pneumococcus after vaccination with PCV remains roughly constant as other serotypes take up the mucosal territory vacated by the pneumococcal serotypes included in the vaccine (115, 117). Most nonvaccine pneumococcal serotypes are less invasive than vaccine serotypes, but they can still cause disease, including pneumonia, and serotype-replacement disease has reduced the benefits of immunization by about one-sixth in the United States (109). Among Alaska Native children aged under 2 years, however, serotype-replacement disease has been more dramatic, reducing the direct benefits of vaccination by 50% (118). Increasing the vaccine valency would overcome this problem, although the complexity of conjugation and the 91 different potential serotypes limit the feasibility of this approach. Given evidence of the substantial direct protection afforded by PCVs, the Global Alliance on Vaccines and Immunization is supporting the introduction of the only commercially available formulation, 7-valent PCV, into several developing countries in 2008.
with operational effectiveness studies due to be performed in The Gambia and Kenya. The relative magnitude of herd protection and serotype-replacement disease observed in these studies will be a strong determinant of the value of this program.

Other vaccines against pneumococcal pneumonia. Immuneopidemiological studies in developing countries suggest that childhood exposure through nasopharyngeal carriage and intermittent pneumococcal invasion generates immune responses to noncapsular antigens (119). This has led to the search for common surface proteins that could overcome the restricted serotype coverage of capsular polysaccharide PCVs. Candidate proteins include pneumolysin, two pneumococcal surface proteins that have a choline-binding function (PspA and PspC), a metal-binding transporter, pneumococcal surface adhesin A (PsaA), and two pneumococcal histidine triad proteins (PhtB and PhtE). Each protein elicits antibodies that protect against systemic challenge in animal models, and protection is increased by combining proteins (120, 121). Reverse vaccinology — deriving antigens from the pneumococcal genome — has also revealed new surface-expressed antigens, including the newly identified pneumococcal pilin (122). PspA elicits antibodies in humans that are protective in mice against fatal intravenous challenge with pneumococci, but there are as yet no reports of successful human protection using protein vaccines (123).

Intriguingly, mouse studies using inactivated, uncleavaged, whole-cell pneumococci as a vaccine have shown protection (124), which is abrogated in mice that lack CD4+ T cells congenitally and in mice depleted of CD4+ T cells using monoclonal antibodies, suggesting that protection against pneumococcal colonization is mediated by CD4+ T cells (125). Although there is no direct experimental evidence for this in humans, a better understanding of the immune responses to bacterial respiratory pathogens would open up new avenues for vaccine development.

An alternative approach to prevent pneumococcal pneumonia in young infants is to immunize the mother and increase the level of pneumococcal-specific antibody passed to the baby via either the placenta or breast milk. Researchers analyzed the outcomes of infants from Papua New Guinea whose mothers had enrolled into a trial of a 14-valent pneumococcal polysaccharide vaccine around the time of birth (124). In children who were aged 1–7 months when their mothers enrolled, and therefore were probably breastfeeding, the incidence of pneumonia was substantially lower among children of vaccinated mothers than among children of mothers in the control group (254 vs. 303 per 1,000 person-years of observation; ref. 126). Subsequently, a number of studies have confirmed the safety of pneumococcal polysaccharide vaccines during pregnancy and documented useful levels of antibody in infant serum and breast milk (127). This remains a strategy with considerable potential for preventing pneumococcal pneumonia in young infants and is under active investigation in northern Australia.

Vaccination against pneumonia and bronchiolitis caused by infection with RSV. RSV is the pneumonia-causing pathogen that poses the most complex challenges for vaccine development. It causes a broad spectrum of disease severity from coryza (runny nose) through bronchiolitis to alveolar pneumonia in infants, especially those aged under 3 months. In The Gambia, RSV is detectable in one-fifth of children admitted to hospitals with lower respiratory tract infections (LRTIs) (128). The annual incidence of severe pneumonia caused by RSV is 5–10 per 1,000 children under 5 years of age in several developing countries (128–130), and an effective RSV vaccine could have substantial impact on childhood pneumonia.

Unfortunately, unexpected results from early studies have severely hampered the development of RSV vaccines (131, 132). A vaccine containing formalin-inactivated RSV administered to children in the 1960s not only failed to protect against infection, but enhanced the frequency and severity of pulmonary disease following natural infection (132). In one study, nearly 80% of vaccinees were hospitalized with a LRTI compared with 5% of control children (132). Furthermore, immunity following clearance of a RSV infection does not prevent reinfection, although it does lead to a reduction in the severity of illness and a switch from lower to upper respiratory tract disease (133, 134). Immunity is both humoral and cell mediated at different stages of infection; neutralizing antibodies specific for the F and G glycoproteins protect against infection, and RSV-specific CTLs terminate an infective episode. Natural exposure to RSV stimulates a balanced CD4+ Th cell response with both proinflammatory Th1 cells (secreting IFN-γ) and antiinflammatory Th2 cells (secreting IL-10). However, one hypothesis explaining disease enhancement among the infants administered the vaccine containing formalin-inactivated RSV is that the vaccine biased the immune system to produce a predominantly Th2 response upon later exposure to virus (135). Ideally, vaccines against RSV disease should induce the same balanced Th1/Th2 response of natural immunity. They should also cover the antigenically distinct groups RSV A and RSV B.

Despite this immunological challenge, there are optimistic developments, particularly with subunit (purified F glycoprotein, G glycoprotein, and matrix proteins) and live-attenuated vaccines. A cold-passaged (cp) derivative of RSV, which caused mild respiratory illness in young children, has been attenuated further by chemical mutagenesis to produce temperature sensitive (ts) strains of RSV (136). One of these, cpts248/404, which was highly attenuated in RSV-seronegative children, proved immunogenic when delivered intranasally to young infants (1–2 months old) but caused unacceptable nasal congestion (137). In an iterative testing process, recombinant technology is being used to manipulate this strain to develop a vaccine that is hoped will have optimal immunogenicity and acceptability (138).

Management of pneumonia cases

The effective management of cases of pneumonia relies on appropriate antibiotic therapy and supportive care, particularly with oxygen in more severe cases. The WHO has promoted case management at the level of community health worker and first-level health facility (139). Initial treatment is with either cotrimoxazole or amoxicillin. Those with lower chest wall indrawing or signs of severe disease, such as convulsions or an inability to drink, are referred to a hospital for inpatient care. A meta-analysis of field trials of the introduction of pneumonia treatment in the community, implemented by simply trained health workers using oral antibiotics, concluded that the intervention was associated with a surprising 20% impact on infant mortality of any cause and a greater impact on mortality in neonates and children 1–5 years old (140). However, this impact was seen in settings where access to antibiotics was very limited prior to the intervention; such an impact cannot be generalized to settings where antibiotic therapy is already widely available.

Since 1992, the management of cases of childhood pneumonia has been incorporated into a broader strategy known as Integrated Management of Childhood Illness (IMCI), which was developed by the WHO and is now the standard of care for sick children in most...
developing countries. So far, IMCI has only been introduced into communities that already have access to health care, thus excluding children whose risk of mortality is highest (141). Children in the poorest communities are at the highest risk of developing conditions such as pneumonia, yet they are least likely to be able to access interventions, leading to inequity — unfair inequality — in child survival. By training community health workers to implement IMCI, the WHO aims to extend its reach beyond existing health services and to improve equity of access. Work in the field of equity has largely concentrated on analyses of access to interventions and on mortality risk by wealth quintiles (142), comparing the richest quintile of a population with the poorest. In many settings, this fails to identify the main determinants of risk, which might be geographic or ethnographic rather than financial. Further research is needed to define the parameters of equity and develop systems to monitor changes.

The impact of antimicrobial resistance on the management of childhood pneumonia is unclear. Rates of resistance to cotrimoxazole among strains of S. pneumoniae and H. influenzae are variable but generally very high, particularly in southern Africa, where many children and adults infected with HIV now receive long-term treatment with cotrimoxazole to prevent pneumonia caused by Pneumocystis jiroveci (143, 144). Although studies have repeatedly failed to establish a link between cotrimoxazole resistance and failure to respond to treatment for pneumonia (145, 146), amoxicillin is now preferred as a first-line treatment for pneumonia, although higher doses might be required in settings for drugs, vaccines, or care. The ambiguity of its various acronyms (e.g., ARI and LRTI) further underlines its perception as a single, tractable problem. The vigorous response to SARS and the considerable support for pandemic influenza preparedness (≈$10 billion) by the global public health community demonstrate what can be achieved when the world perceives a substantial health threat. Pneumonia, with a global burden of 5,000 childhood deaths every day, is a continuous, tangible threat that should trigger similar responses — action and research on pneumonia are urgently required.

Research on pneumonia is also very likely to be effective, especially if the problem is tackled comprehensively. A far-reaching approach should include (a) a better understanding of the epidemiology of fatal pneumonia, and to investigate the role of equity in death from pneumonia in childhood.

Acknowledgments

J.A.G. Scott is funded by the Wellcome Trust of Great Britain through a senior fellowship in clinical science (no. 061089). J.S.M. Peiris is funded by Central Allocation Grant HKU1/05C from the Research Grants Council of Hong Kong. The authors are grateful to Angela Hwang of the Bill and Melinda Gates Foundation for help with the preparation of the manuscript.

Address correspondence to: J. Anthony G. Scott, Wellcome Trust/KEMRI Collaborative Research Programme, PO Box 230, Kilifi 80108, Kenya. Phone: 254-41-522063; Fax: 254-41-522390; E-mail: ascott@ikilifi.net.


